DEUX NOUVEAUX ANTICOAGULANTS : DABIGATRAN ETEXILATE ET RIVAROXABAN

Abstract

In the long list of anticoagulants in development, two molecules have obtained Marketing Authorization in a
around one hundred countries except the USA, in thromboprophylaxis in adults operated on with implantation
a hip or knee prosthesis. Other indications are under development: prevention in the environment
medical, treatment of thrombosis and pulmonary embolism and secondary prevention of recurrence, prevention
cerebrovascular accidents (stroke) in nonvalvular atrial fibrillation. An indication in acute coronary syndromes is also under development in association with one or more agents
antiplatelet drugs.